The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Androgen Receptor Coactivators Lysine-Specific Histone Demethylase 1 and Four and a Half LIM Domain Protein 2 Predict Risk of Prostate Cancer Recurrence
Abstract
Prostate cancer biology varies from locally confined tumors with low risk for relapse to tumors with high risk for progression even after radical prostatectomy. Currently, there are no reliable biomarkers to predict tumor relapse and poor clinical outcome. In this study, we correlated expression patterns of the androgen receptor (AR) coactivators lysine-specific histone demethylase 1 (LSD1) and four and a half LIM-domain protein 2 (FHL2), AR, Gleason score, Gleason grade, and p53 expression in clinically organ confined prostate cancers with relapse after radical prostatectomy. Our data reveal that high levels of LSD1, nuclear expression of the FHL2 coactivator, high Gleason score and grade, and very strong staining of nuclear p53 correlate significantly with relapse during follow-up. No correlation exists with relapse and the expression of AR and cytoplasmic expression of FHL2. To confirm these data, we did quantitative reverse transcription-PCR and Western blot analyses in a subset of tumor specimens. Consistently, both LSD1 mRNA and protein levels were significantly up-regulated in high-risk tumors. We previously identified LSD1 and FHL2 as nuclear cofactors interacting specifically with the AR in prostate cells and showed that both stimulate androgen-dependent gene transcription. Our present study suggests that LSD1 and nuclear FHL2 may serve as novel biomarkers predictive for prostate cancer with aggressive biology and point to a role of LSD1 and FHL2 in constitutive activation of AR-mediated growth signals. (Cancer Res 2006; 66(23): 11341-7)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gleason, D. F., Mellinger, G. T., & The Veterans Administration Cooperative Urological Research Group Members of this group areS0022534717598894-57c401330b4195dbd1713587ed540477 Lino J. Arduino Veterans Administration Center (VAC), D. M. (1974) · Journal of Urology · doi:10.1016/s0022-5347(17)59889-4 · Cited by 2,214
Remmele, W., & Stegner, H.-E. (1987) · PubMed · Cited by 1,976
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
Metzger, E., Wissmann, M., Yin, N., Müller, J. M., Schneider, R., Peters, A. H. F. M., Günther, T., Buettner, R., & Schüle, R. (2005) · Nature · doi:10.1038/nature04020 · Cited by 1,733
Self-citationGlobal histone modification patterns predict risk of prostate cancer recurrence
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., & Kurdistani, S. K. (2005) · Nature · doi:10.1038/nature03672 · Cited by 1,092
International trends and patterns of prostate cancer incidence and mortality
Hsing, A. W., Tsao, L., & Devesa, S. S. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000101)85:1<60::aid-ijc11>3.0.co;2-b · Cited by 846
A history of prostate cancer treatment.
Denmeade, S. R., & Isaacs, J. T. (2002) · Nature reviews. Cancer · doi:10.1038/nrc801 · Cited by 591
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
Taplin, M., & Balk, S. P. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10653 · Cited by 390
FHL2, a novel tissue-specific coactivator of the androgen receptor
Muller, J. M. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.359 · Cited by 326
Wardelmann, E., Losen, I., Hans, V., Neidt, I., Speidel, N., Bierhoff, E., Heinicke, T., Pietsch, T., Büttner, R., & Merkelbach‐Bruse, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.11323 · Cited by 223
Li, R., Wheeler, T., Dai, H., Frolov, A., Thompson, T., & Ayala, G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200407000-00013 · Cited by 186
Cited by
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487
Dynamic Regulation of Histone Lysine Methylation by Demethylases
Shi, Y., & Whetstine, J. R. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.010 · Cited by 707
Reversal of Histone Methylation: Biochemical and Molecular Mechanisms of Histone Demethylases
Mosammaparast, N., & Shi, Y. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.070907.103946 · Cited by 585
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., Ciceri, F., Blaser, J. G., Greystoke, B. F., Jordan, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.014 · Cited by 566
Hayami, S., Kelly, J. D., Cho, H., Yoshimatsu, M., Unoki, M., Tsunoda, T., Field, H. I., Neal, D. E., Yamaue, H., Ponder, B. A. J., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25349 · Cited by 489
Metadata
- Authors
- Kahl, P., Gullotti, L., Heukamp, L. C., Wolf, S., Friedrichs, N., Vorreuther, R., Solleder, G., Bastian, P. J., Ellinger, J., Metzger, E., Schüle, R., & Buettner, R.
- Venue
- Cancer Research
- Published
- 2006-12-01
- Volume
- 66
- Issue
- 23
- Pages
- 11341-11347
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2130211801
- Cited by
- 469
- References
- 18
- FWCI
- 14.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Androgen Receptor Coactivators Lysine-Specific Histone Demethylase 1 and Four and a Half LIM Domain Protein 2 Predict Risk of Prostate Cancer Recurrence. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-1570
- The paper
- Kahl, P., Gullotti, L., Heukamp, L. C., Wolf, S., Friedrichs, N., Vorreuther, R., Solleder, G., Bastian, P. J., Ellinger, J., Metzger, E., Schüle, R., & Buettner, R. (2006). Androgen Receptor Coactivators Lysine-Specific Histone Demethylase 1 and Four and a Half LIM Domain Protein 2 Predict Risk of Prostate Cancer Recurrence. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-1570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
